NEXMED ANNOUNCES NEW PATENT ALLOWANCE FOR ALPROX-TD

NexMed, Inc., a developer of innovative treatments based on the NexACT drug delivery technology, has announced that it has received a Notice of Allowance from the U.S. Patent & Trademark Office for its U.S. patent application entitled, "Prostaglandin Compositions & Methods of Treatment for Male Erectile Dysfunction." The 37 allowed claims extend to NexMed's proprietary topical treatment for erectile dysfunction -- Alprox-TD, and specifically, to the product's enabling technology, formulation and method of treatment. INS News (http://feed.insnews.org/v-cgi/feeds.cgi?feedid=149&story_id=1979835)